Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.

Current securities

1. Regulation FD Disclosure · Other EventsSep 24, 2026
2. Regulation FD Disclosure · Other EventsSep 14, 2026
3. 144 filingSep 8, 2026
4. 4 filingAug 14, 2026
5. Regulation FD Disclosure · Other EventsAug 13, 2026